for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Allergan plc

AGN.N

Latest Trade

167.16USD

Change

0.69(+0.41%)

Volume

297,884

Today's Range

165.86

 - 

167.80

52 Week Range

114.27

 - 

197.00

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
166.47
Open
166.21
Volume
297,884
3M AVG Volume
102.32
Today's High
167.80
Today's Low
165.86
52 Week High
197.00
52 Week Low
114.27
Shares Out (MIL)
328.10
Market Cap (MIL)
54,618.31
Forward P/E
9.96
Dividend (Yield %)
1.78

Next Event

Allergan plc Annual Shareholders Meeting

Latest Developments

More

FDA - Allergan Recalls Natrelle Biocell Textured Breast Implants Due To Risk Of BIA-ALCL Cancer

Molecular Partners Says U.S. Marketing Application Accepted For Abicipar Pegol In Patients With Macular Degeneration

Allergan Receives FDA Approval of Juvederm VOLUMA XC For Mid-Face Injection Via Cannula

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Allergan plc

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products. The US General Medicine segment includes sales relating to branded products within the United States that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women's Health, Anti-Infectives and Diversified Brands. The International segment includes sales relating to products sold outside the United States.

Industry

Biotechnology & Drugs

Contact Info

Clonshaugh Business And Technology Park

+353.21.65235000

https://www.allergan.com/

Executive Leadership

Brenton L. Saunders

Chairman of the Board, President, Chief Executive Officer

Matthew M. Walsh

Chief Financial Officer

Karen Lee Ling

Chief Human Resource Officer

Wayne R. Swanton

Executive Vice President - Global Operations

James C. D'Arecca

Chief Accounting Officer

Key Stats

2.67 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

14.6K

2017

15.9K

2018

15.8K

2019(E)

15.5K
EPS (USD)

2016

13.510

2017

16.350

2018

16.690

2019(E)

16.707
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.48
Price To Book (MRQ)
0.91
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
38.05
LT Debt To Equity (MRQ)
32.86
Return on Investment (TTM)
-8.96
Return on Equity (TTM)
-8.33

Latest News

Consumer groups, unions urge caution on $63 billion AbbVie deal for Allergan

About a dozen advocacy groups and unions, including Public Citizen and the American Federation of Teachers, wrote the Federal Trade Commission on Thursday urging it to consider blocking drugmaker AbbVie Inc's <ABBV.N> planned $63 billion purchase of Botox maker Allergan...

UPDATE 2-Drugmakers Endo, Allergan agree to $15 mln in settlements in major opioid case

Endo International Plc and Allergan Plc have agreed to pay $15 million to avoid going to trial in October in a landmark case by two Ohio counties accusing various drug manufacturers and distributors of fueling the U.S. opioid epidemic.

Evolus reports sales of its Botox rival ahead of expectations

Medical aesthetics company Evolus Inc <EOLS.O> on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's <AGN.N> Botox, which has dominated the medical aesthetics market for more than a decade.

Evolus says launch of its Botox rival ahead of its expectations

Evolus Inc on Monday reported revenue of $2.3 million from early sales of its newly launched rival to Allergan Plc's Botox, ahead of its own expectations.

Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand

Allergan Plc <AGN.N>, which is being bought by AbbVie Inc <ABBV.N> for $63 billion, beat quarterly profit estimates and raised its 2019 revenue forecast on Tuesday, helped by demand for its dry eye drug Restasis and aesthetics product Juvederm.

AbbVie spotlights Allergan deal, new drugs as Humira sales wane

AbbVie Inc <ABBV.N> said on Friday a combination of new drugs in its arsenal and its planned $63 billion deal for Botox-maker Allergan Plc <AGN.N> will counter declining sales of its long-time bestseller, Humira.

Allergan recalls textured breast implants worldwide

Allergan Plc said on Wednesday it was recalling its Biocell textured breast implants and tissue expanders across markets, citing concerns over a rare form of cancer, after the U.S. health agency asked the drugmaker to pull the products.

Allergan recalls textured breast implants across markets

Allergan Plc said on Wednesday it was recalling Biocell textured breast implants and tissue expanders across all markets following the updated safety information from the U.S. Food And Drug Administration.

AbbVie looks beyond Humira with $63 billion deal for Botox-maker Allergan

Drugmaker AbbVie Inc said on Tuesday it would acquire Allergan Plc for about $63 billion (£49.6 billion), giving AbbVie control over the lucrative wrinkle treatment Botox and buying time to seek new growth before its blockbuster arthritis treatment Humira loses U.S. patent...

US STOCKS-Wall St dragged down by Iran tensions, trade worries; Fed in focus

* Indexes down: 0.21%, S&P 0.41%, Nasdaq 0.75% (Changes comment, adds details, updates prices)

AbbVie nears deal to buy Allergan for more than $60 bln - WSJ

AbbVie Inc is nearing a deal to buy Botox-maker Allergan PLC for more than $60 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.

Allergan to recall textured breast implants in Canada

Allergan Plc said on Tuesday it will voluntarily recall and stop the sale of its Biocell textured breast implants in Canada after the country's health agency suspended the company's licenses for the implants, citing increased risk of cancer.

Allergan to recall textured breast implants in Canada

Allergan Plc said on Tuesday it will voluntarily recall its textured breast implants from the Canadian market, after the country's health regulator suspended the company's licenses for its Biocell implants, citing increased risk of cancer.

Allergan's Vraylar wins FDA approval for bipolar depression

Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, expanding its scope of treatment to a full spectrum of symptoms related to the condition, the company said on Monday.

Allergan's Vraylar wins FDA approval for bipolar depression

Allergan Plc's Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, making it a treatment option for a full spectrum of the condition's cyclical symptoms, the company said on Monday.

Allergan CEO says company is urgently looking at all options to boost share price

Allergan Plc Chief Executive Brent Saunders said on Tuesday that he and the board of directors were looking with a sense of urgency at all options to revive the Botox maker's falling share price, but a lack of specifics failed to boost investor sentiment.

Allergan reports bigger first-quarter loss on $2.5 bln charge

Allergan Plc posted a bigger first-quarter loss on Tuesday as it recorded a charge of about $2.5 billion related to the clinical failure of its depression treatment candidate rapastinel.

Allergan CEO Saunders wins vote to keep chairman role

Allergan Plc shareholders have voted down a nonbinding proposal that sought an immediate split of the roles of chairman and chief executive, with 61.3 percent of shareholders backing Chairman and CEO Brent Saunders.

CORRECTED-UPDATE 1-Allergan CEO Saunders wins vote to keep chairman role

Allergan Plc shareholders have voted down a non-binding proposal that sought an immediate split of the roles of chairman and chief executive, with 61.3 percent of shareholders backing Chairman and CEO Brent Saunders.

CORRECTED-Allergan CEO Saunders wins vote to keep chairman role

Allergan Plc shareholders have voted down a non-binding proposal that sought an immediate split of the roles of chairman and chief executive, with 61.3 percent of shareholders backing Chairman and CEO Brent Saunders.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up